Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by $0.03, Bloomberg Earnings reports. The company had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. Ionis Pharmaceuticals’s quarterly revenue was up 170.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.47) EPS.

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded down 6.22% during mid-day trading on Tuesday, reaching $49.29. 845,393 shares of the company’s stock traded hands. The company’s 50 day moving average is $53.06 and its 200-day moving average is $46.75. The firm’s market cap is $6.11 billion. Ionis Pharmaceuticals has a 52 week low of $24.58 and a 52 week high of $60.01.

Several research analysts have issued reports on IONS shares. Leerink Swann reaffirmed an “outperform” rating and issued a $45.00 price target (down previously from $47.00) on shares of Ionis Pharmaceuticals in a report on Wednesday, May 17th. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Monday, July 31st. TheStreet raised Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Wednesday, July 5th. BMO Capital Markets reaffirmed a “buy” rating and issued a $59.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, June 2nd. Finally, Piper Jaffray Companies set a $51.00 price target on Ionis Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 10th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $46.44.

In related news, Chairman Stanley T. Crooke sold 16,500 shares of the firm’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $52.45, for a total transaction of $865,425.00. Following the sale, the chairman now directly owns 53,014 shares in the company, valued at $2,780,584.30. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP C Frank Bennett sold 10,000 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $59.29, for a total transaction of $592,900.00. Following the sale, the senior vice president now owns 25,041 shares in the company, valued at $1,484,680.89. The disclosure for this sale can be found here. Over the last quarter, insiders sold 54,379 shares of company stock worth $2,946,052. Company insiders own 1.86% of the company’s stock.

Several large investors have recently modified their holdings of the company. Prudential Financial Inc. raised its stake in shares of Ionis Pharmaceuticals by 4.9% in the second quarter. Prudential Financial Inc. now owns 8,641 shares of the company’s stock worth $440,000 after buying an additional 400 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after buying an additional 800 shares during the last quarter. Aviva PLC bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth approximately $10,187,000. Cadence Capital Management LLC bought a new stake in shares of Ionis Pharmaceuticals during the second quarter worth approximately $600,000. Finally, Sicart Associates LLC raised its stake in shares of Ionis Pharmaceuticals by 5.4% in the second quarter. Sicart Associates LLC now owns 387,322 shares of the company’s stock worth $19,703,000 after buying an additional 19,962 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

WARNING: “Ionis Pharmaceuticals, Inc. (IONS) Releases Quarterly Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/08/ionis-pharmaceuticals-inc-nasdaqions-posts-earnings-results-misses-estimates-by-0-06-eps.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.